Loading...
Presenters at the 2022 American Society of Hematology (ASH) annual meeting, held December 10–13 in New Orleans, reported the latest research in hematology. NEJM Group was on hand to cover the meeting. Here, NEJM Journal Watch Oncology and Hematology reports some of the key findings in hematologic malignancies and Associate Editor Dr. Michael E. Williams provides clinical perspective. Abstracts can be found on the ASH meeting site.
Talquetamab, an investigational bispecific antibody that binds to CD3 and GPRC5D receptors, had significant antitumor effects in patients with heavily pretreated relapsed or refractory (R/R) multiple myeloma, according to the industr…